12 Month Price Forecast For NKTX
Distance to NKTX Price Forecasts
NKTX Price Momentum
🤔 Considering Nkarta (NKTX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 4:20 AM UTC
NKTX Analyst Ratings & Price Targets
Based on our analysis of 10 Wall Street analysts, NKTX has a consensus that is bullish. The median price target is $15.50, with forecasts ranging from $11.00 to $20.00. Currently, there are 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With NKTX currently trading at $2.48, the median price forecast suggests a 525.0% upside. The most optimistic forecast comes from Emily Bodnar at HC Wainwright & Co., projecting a 706.5% upside, while Gil Blum at Needham provides the most conservative target, suggesting a 343.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NKTX Analyst Consensus
NKTX Price Target Range
Latest NKTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NKTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 21, 2024 | Mizuho | Salim Syed | Outperform | Maintains | $16.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $18.00 |
| Nov 8, 2024 | Needham | Gil Blum | Buy | Maintains | $11.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $22.00 |
| Aug 14, 2024 | Needham | Gil Blum | Buy | Reiterates | $13.00 |
| Aug 14, 2024 | Raymond James | Laura Prendergast | Strong Buy | Upgrade | $16.00 |
| Jul 24, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $23.00 |
| Jun 28, 2024 | Needham | Gil Blum | Buy | Reiterates | $13.00 |
| Jun 27, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $23.00 |
| May 13, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $23.00 |
| May 13, 2024 | Needham | Gil Blum | Buy | Maintains | $13.00 |
| May 10, 2024 | Canaccord Genuity | Bill Maughan | Buy | Maintains | $15.00 |
| Apr 10, 2024 | Needham | Gil Blum | Buy | Reiterates | $15.00 |
| Mar 26, 2024 | Canaccord Genuity | Bill Maughan | Buy | Maintains | $16.00 |
| Mar 25, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $22.00 |
| Mar 22, 2024 | Needham | Gil Blum | Buy | Reiterates | $15.00 |
| Mar 22, 2024 | Mizuho | Salim Syed | Buy | Maintains | $25.00 |
| Mar 22, 2024 | Raymond James | Laura Prendergast | Outperform | Downgrade | $16.00 |
| Mar 22, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $20.00 |
| Mar 5, 2024 | Mizuho | Salim Syed | Buy | Maintains | $31.00 |
Stocks Similar to Nkarta Inc
The following stocks are similar to Nkarta based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Nkarta Inc (NKTX) Financial Data
Nkarta Inc has a market capitalization of $165.48M with a P/E ratio of -1.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -30.4%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Nkarta Inc (NKTX) Company Overview
About Nkarta Inc
Develops cell therapies for cancer treatment.
Nkarta, Inc. operates as a clinical-stage biopharmaceutical company, focusing on the development and commercialization of natural killer cell therapies. The company generates revenue by advancing its innovative product candidates through clinical trials and eventually bringing them to market to treat various cancers and autoimmune diseases.
Nkarta's lead product, NKX019, is currently in Phase 1 trials for non-hodgkin lymphoma and lupus nephritis, while other candidates like NKX101 and NKX070 are targeting different cancers. The company has a strategic research collaboration with CRISPR Therapeutics AG and was founded in 2015, headquartered in South San Francisco, California.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
159
CEO
Mr. Paul J. Hastings
Country
United States
IPO Year
2020
Website
www.nkartatx.comNkarta Inc (NKTX) Latest News & Analysis
Ntrust-2 is now enrolling patients with systemic sclerosis, myositis, and ANCA-associated vasculitis across three parallel cohorts.
The Ntrust-2 trial's enrollment for systemic sclerosis, myositis, and ANCA-associated vasculitis may indicate advancing clinical research, potentially impacting related biotech stocks and market sentiment.
Nkarta, Inc. (Nasdaq: NKTX) will participate in an upcoming investor conference, focusing on its development of engineered natural killer cell therapies.
Nkarta's participation in an investor conference may signal upcoming developments or insights into its NK cell therapies, potentially impacting investor sentiment and stock performance.
Nkarta, Inc. (Nasdaq: NKTX) reported its Q3 2024 financial results on November 7, 2024. The company is focused on developing engineered NK cell therapies.
Nkarta's Q3 financial results may indicate its progress in developing NK cell therapies, impacting its stock performance and future funding prospects in the biopharmaceutical sector.
The health care sector's most oversold stocks may offer investment opportunities in undervalued companies.
Oversold health care stocks indicate potential bargains, signaling a buy opportunity for investors seeking value growth in a recovering market.
Nkarta, Inc. (Nasdaq: NKTX) will participate in an upcoming investor conference, focusing on its engineered natural killer cell therapies.
Nkarta's participation in an investor conference signals potential updates on its NK cell therapies, which could influence stock performance and investor sentiment.
Why Nkarta Stock Is Soaring Today
5 months agoRaymond James upgraded Nkarta stock to a strong buy, citing the company's robust cash position and potential for its lead candidate NKX019.
Nkarta's upgrade to a strong buy highlights confidence in its financial health and growth potential, signaling a favorable outlook that could attract more investment interest.
Frequently Asked Questions About NKTX Stock
What is Nkarta Inc's (NKTX) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Nkarta Inc (NKTX) has a median price target of $15.50. The highest price target is $20.00 and the lowest is $11.00.
Is NKTX stock a good investment in 2025?
According to current analyst ratings, NKTX has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.48. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for NKTX stock?
Wall Street analysts predict NKTX stock could reach $15.50 in the next 12 months. This represents a 525.0% increase from the current price of $2.48. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Nkarta Inc's business model?
Nkarta, Inc. operates as a clinical-stage biopharmaceutical company, focusing on the development and commercialization of natural killer cell therapies. The company generates revenue by advancing its innovative product candidates through clinical trials and eventually bringing them to market to treat various cancers and autoimmune diseases.
What is the highest forecasted price for NKTX Nkarta Inc?
The highest price target for NKTX is $20.00 from Emily Bodnar at HC Wainwright & Co., which represents a 706.5% increase from the current price of $2.48.
What is the lowest forecasted price for NKTX Nkarta Inc?
The lowest price target for NKTX is $11.00 from Gil Blum at Needham, which represents a 343.5% increase from the current price of $2.48.
What is the overall NKTX consensus from analysts for Nkarta Inc?
The overall analyst consensus for NKTX is bullish. Out of 10 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $15.50.
How accurate are NKTX stock price projections?
Stock price projections, including those for Nkarta Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
